Synapse - Works

Results (22056)

Association between renal function and chemotherapy-related toxicity in older adults with cancer

Meeting Abstract

Peterson, L. L.; Hurria, A.; Feng, T.; Mohile, S. G.; Owusu, C.; Klepin, H. D.; Gross, C. P.; Lichtman, S. M.; Gajra, A.; Glezerman, I. G.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations

Meeting Abstract

Patel, M. R.; Bauer, T. M.; Liu, S. V.; Drilon, A. E.; Wheler, J. J.; Shaw, A. T.; Farago, A. F.; Ou, S. H. I.; Luo, D.; Yeh, L.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping

Meeting Abstract

Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer

Meeting Abstract

Page, D. B.; Wen, Y. H.; Brogi, E.; Yuan, J. D.; Emerson, R. O.; Patil, S.; Dang, C. T.; Norton, L.; Hudis, C. A.; Mcarthur, H. L.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI)

Meeting Abstract

Page, D. B.; Mariotti, V.; Davydov, O.; Patil, S.; Hans, D.; Hudis, C. A.; Farooki, A.; Fornier, M. N.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Meeting Abstract

Oxnard, G. R.; Ramalingam, S. S.; Ahn, M. J.; Kim, S. W.; Yu, H. A.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Cantarini, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial

Meeting Abstract

Owens, C. N.; Iannotta, A.; Gerecitano, J. F.; Matasar, M. J.; Noy, A.; Moskowitz, C. H.; Drullinsky, P.; Palomba, M. L.; Straus, D. J.; Horwitz, S. M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors

Meeting Abstract

Ott, P. A.; Callahan, M. K.; Odunsi, K.; Park, A. J.; Pan, L. S.; Venhaus, R. R.; Karakunnel, J. J.; Hodi, F. S.; Wolchok, J. D.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy

Meeting Abstract

O'Reilly, E. M.; Walker, C.; Clark, J.; Brill, K. J.; Dawkins, F. W.; Bendell, J. C.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results

Meeting Abstract

O'Reilly, E. M.; Mahalingam, D.; Roach, J. M.; Schultes, B. C.; Rosano, M. E.; Miller, P. J.; Wolf, J.; Flaherty, K.; Ryan, D. P.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save